Vigil Neuroscience Touts Positive Healthy Volunteer Data From Lead Program In Rare Neurological Disease

Vigil Neuroscience Inc VIGL announced interim topline results from its ongoing Phase 1 trial of VGL101, its lead product candidate, in healthy volunteers.
These interim data support the initiation of a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) with a 20 mg/kg dose.
All adverse events (AEs) were mild in severity except for one moderate AE of dizziness, and all AEs resolved without intervention. No serious adverse events have been reported to date.
VGL101 showed dose-proportional PK with a favorable half-life and brain penetration.
VGL101 achieved dose-dependent, durable decreases in levels of sTREM2 in the cerebrospinal fluid (CSF), demonstrating proof of target engagement.
VGL101 20 mg/kg repeat dosing was associated with a robust reduction in sTREM2 levels, and decreases were observed 28 days after the third and final dose.
The Company continues to dose escalate in its Phase 1 trial in healthy volunteers and has been cleared to initiate a 60 mg/kg cohort in Australia.
Vigil is on track to initiate the VGL101 Phase 2 trial in ALSP patients with a 20 mg/kg dose this quarter.
Price Action: VIGL shares are down 0.79% at $15.00 on the last check Wednesday.